{
    "nct_id": "NCT03141177",
    "official_title": "A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma",
    "inclusion_criteria": "* Histological confirmation of RCC with a clear-cell component, including participants who may also have sarcomatoid features\n* Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCC\n* No prior systemic therapy for RCC with the following exception:\n\n  i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any active CNS metastases\n* Any active, known or suspected autoimmune disease\n* Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization\n* Participants who have received a live/attenuated vaccine within 30 days of first treatment\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com"
}